Card Payment: Please notify us that you wish to cancel your order
These advancements position microneedle technology as a transformative approach for delivering GLP-1 receptor agonists, offering the potential to improve therapeutic adherence, minimize systemic side effects, and support decentralized care models for diabetes management [43]
*Average weight loss based on 68 and 72 week clinical trials studying semaglutide (2.4 mg) and tirzepatide (10-15 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related health condition, the average weight loss was 15% and 20% respectively
However, patients should be cautioned that exercise capacity may be temporarily reduced during the initial treatment period, and expectations should be adjusted accordingly
When drug-induced obesity is documented, code E66.1 plus the appropriate adverse effect code from T36T50 with 5th/6th character A (initial encounter), D (subsequent), or S (sequela)
However, if you experience severe pain, numbness, or weakness, seek medical evaluation to rule out other causes
